Cited by 844Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsBlood Pressure and Hypertension Studies

Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study

Open access
Freeman, Dilys J., Norrie, John, Sattar, Naveed, Neely, R. Dermot G., Cobbe, Stuart M., Ford, Ian, Isles, Christopher, Lorimer, A. Ross +5 more·2001·Circulation

Abstract

Background —We examined the development of new diabetes mellitus in men aged 45 to 64 years during the West of Scotland Coronary Prevention Study. Methods and Results —Our definition of diabetes mellitus was based on the American Diabetic Association threshold of a blood glucose level of ≥7.0 mmol/L. Subjects who self-reported diabetes at baseline or had a baseline glucose level of ≥7.0 mmol/L were excluded from the analyses. A total of 5974 of the 6595 randomized subjects were included in the analysis, and 139 subjects became diabetic during the study. The baseline predictors of the transition from normal glucose control to diabetes were studied. In the univariate model, body mass index, log triglyceride, log white blood cell count, systolic blood pressure, total and HDL cholesterol, glucose, and randomized treatment assignment to pravastatin were significant predictors. In a multivariate model, body mass index, log triglyceride, glucose, and pravastatin therapy were retained as predictors of diabetes in this cohort. Conclusions —We concluded that the assignment to pravastatin therapy resulted in a 30% reduction ( P =0.042) in the hazard of becoming diabetic. By lowering plasma triglyceride levels, pravastatin therapy may favorably influence the development of diabetes, but other explanations, such as the anti-inflammatory properties of this drug in combination with its endothelial effects, cannot be excluded with these analyses.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.103.3.357

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Recent post-hoc analyses show a possible protective effect on the development of diabetes of the ACE inhibitor ramipril and the HMG CoA reductase inhibitor pravastatin.

    “The recent post-hoc analyses showing a possible protective effect on the development of diabetes of the ACE inhibitor ramipril [163] and the HMG CoA reductase inhibitor pravastatin [165] are enticing and emphasise that there are many aspects of the pathogenesis and treatment of the disease that still need to be uncovered.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. WOSCOPS Study Group. Screening experience and baseline character- istics in the West of Scotland Study. Am J Cardiol. 1995;76:485-491.
  2. Yudkin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol. 1999;19:972-978.

Cited by

Sorted by citations

Authors
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., Packard, C. J., Shepherd, J., & Gaw, A.
Affiliations
Durham University (GB)
Venue
Circulation
Published
2001-01-23
Volume
103
Issue
3
Pages
357-362
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2061489988
Cited by
844
References
32
Citations by year
2026: 6 · 2025: 10 · 2024: 10 · 2023: 14 · 2022: 11 · 2021: 9 · 2020: 9 · 2019: 23 · 2018: 17 · 2017: 18 · 2016: 27 · 2015: 32 · 2014: 37 · 2013: 39 · 2012: 43
FWCI
75.54
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • University of Glasgow
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
pravastatin, diabetes mellitus, statin therapy, hypertriglyceridemia, triglycerides, body mass index, fasting blood glucose, diabetes risk factors, anti-inflammatory activity
MeSH terms
Anticholesteremic Agents, Blood Glucose, Coronary Disease, Diabetes Mellitus, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Triglycerides, Cohort Studies, Body Mass Index, Multivariate Analysis, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review